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Several factors are conspiring to focus attention 
on neonatal immunology. First, the dogma that 
neonatal exposure to antigen results in tolerance 
rather than immunity has been challenged. 
Second, there is a clinical imperative; the 
development of effective neonatal vaccines is 
likely to be extremely important in reducing infant 
morbidity and mortality, and the successful use of 
cord blood stem cells for bone marrow 
reconstitution calls for a better understanding of 
the regulation of responsiveness in neonatal 
lymphocytes. Third, recent evidence suggests that 
exposure to high levels of antigen during early life 
might contribute to the increasing prevalence of 
allergic diseases.  
 
Neonatal B cells 
Although neonates can mount immune responses, 
they are still relatively immunodeficient (Table 1). 
This could reflect inherent, differences between 
adult and neonatal B and/ or T cells or some 
aspect of the neonatal environment that modifies 
their responses. The responsiveness of neonatal T 
cells to antigen has been reviewed recently1. 
 
Table 1. Characteristics of murine neonatal 
antibody responses1 
Antigen type Adults Neonates 
T-independent type 1 
(TI-1) 
++ ++ 
T-independent type 2 
(TI-2) 
++ + 
T-dependent (TD)   
Isotype switching +++ Weak 
Affinity maturation +++ Poor 
0BHeterogeneity +++ Restricted 
 
Neonatal B cells are phenotypically and 
functionally distinct from their adult counterparts 
(Table 2) although the precise differences in 
signaling pathways between adult and neonatal B 
cells remain to be fully elucidated2,3. 
Ligation of the B-cell receptor (BCR), which 
induces activation and proliferation in mature 
adult B cells, fails to have this effect on neonatal 
B cells. Rather, it transduces negative signals that 
inhibit subsequent responses to antigen or mitogen 
and make B cells prone to apoptosis 4,5 
Table 2. Functional and biochemical differences in 
signal transduction following B-cell receptor 
ligation on mature and immature B cells2-3. 
Response Neonatal B cells 
Mature B 
cells 
Proliferation - + 
Apoptosis + - 




FYN expression - + 
FGR I expression - + 
FOS induction - + 
EGR I induction - + 
MYC induction - + 
Cyclin E induction - + 
 
T cell responses 
Although murine studies demonstrate a bias towards 
T helper-2 (Th2) type T-cell responses, this is less 
evident in humans. Human neonatal T cells generally 
produce less interleukin 2 (IL-2), IFN-gamma and 
IL-4 than adult T cells, possibly because of the 
memory status of significant numbers of adult T 
cells. In studies that compare the responses of 
purified CD4 'naive' T cells from neonates with those 
from adults, similar cytokine profiles have been 
observed6. 
Neonatal and adult naive T cells do not differ in 
their ability to produce high levels of Th1-type 
cytokines, or to develop into Th2 effectors upon 
repetitive stimulation. Therefore, if there is a bias in 
human neonatal T cells towards Th2-type cytokine 
production, it cannot be attributed to neonatal T -cell 
immaturity alone, but must also involve contributions 
from other immature or dysregulated accessory cells, 
particularly dendritic cells (DCs) and B cells.  
The responsiveness of human neonatal T cells to 
individual cytokines differs markedly from that of 
adult T cells. Neonatal human T cells proliferate in 
the presence of IL-4 7, and recently, IL-7 has been 
shown to be a potent inducer of proliferation in 
neonatal, but not adult, T cells. IL-7 also acts as a 




viability and expansion for significantly longer 
than adult naive T cells.  
 
T-B interactions in neonates  
B cells of neonates show a selective inability to 
upregulate expression of MHC class-II following 
BCR ligation9 Because antigenic peptides are 
targeted to newly synthesized MHC class II 10, the 
failure of neonatal B cells to induce its 
hyperexpression of class-II must result in a 
reduced array of peptide-loaded MHC at their 
surface. This implies that neonatal B cells are 
likely to deliver weaker signals to T cells via their 
T-cell receptors (TCR). These might be 
insufficient to reach the threshold for T-cell 
activation, and fail to lead to CD40 ligand 
(CD40L) induction and the establishment of a 
productive T-B interaction. This would be 
compounded by the diminished capacity of 
neonatal T cells to upregulate CD40L 
expression11.  
Differences in antigen handling by neonatal B 
cells could also contribute to the reported bias of 
neonatal responses towards those of the Th2 type. 
Experiments that examine Th polarization under 
various conditions of antigen presentation provide 
evidence that low MHC-peptide density, as 
probably occurs in neonates, favours priming of 
Th2-type CD4+ cells. Furthermore, BCR ligation 
does not induce the expression of B7.2 (CD86) on 
neonatal B-cells. Neonatal B-cells are thus 
unlikely to deliver the costimulatory signals to T 
cells via CD28, which are pivotal in defining the 
outcome of TCR ligation. Neonatal B cells might 
thus be expected to be inefficient or ineffective 
APCs and, where they do work, to preferentially 
induce Th2 helper cells and direct Th0 cells 
towards the secretion of cytokines that 
characterize Th2 cells. The inability of neonatal B 
cells to upregulate key molecules that are 
involved in their interaction with T cells might 
also create conditions in which antigen encounter 
results in tolerance -with T cells receiving a 'weak' 
signal-l (low density peptide-loaded MHC class-
II) in the absence of costimulatory signal-2 being 
rendered anergic or even deleted. The failure of 
BCR ligation to induce B7.2 expression on 
neonatal B cells could also contribute to the 
induction of tolerance by enhancing their 
elimination 12.  
Cytokines -a possible role  
As indicated earlier, part of the explanation for 
poor neonatal responses might lie in the 
immaturity of the individual rather than of the B 
cells per se. In addition to the actions of LT-alpha, 
LT-beta and TNF that are mentioned above, recent 
experiments have suggested other cytokines that 
might affect responses in early life.  
IL-10 is made by B1 cells13, which are more 
common in neonates than in adults, and by neonatal 
T cells, which secrete high levels of this cytokine. IL-
10 downregulates the appearance of MHC class II 
complexes at the surface of monocytes and inhibits 
their ability to act as APC 14. It does not, however, 
have similar effects on B cells 13. High levels of IL-
10 in neonates might thus tend to favour B cells that 
act as APC, with the consequences described above.  
Transforming growth factor-beta1 (TGF-beta1) 
also downregulates constitutive MHC class II 
expression by human peripheral blood mononuclear 
cells (presumably including both B cells and 
monocytes). Intriguingly, a genetic modification that 
has resulted in expression of TGF-beta1 in the 
pancreatic islets of non-obese diabetic (NOD) mice 
protects them from diabetes, apparently by altering 
the APC preference of the NOD T cells from B cells 
to macrophages15.  
 
Why do neonates fail to make antibody responses 
to polysaccharide antigens?  
Human neonates are particularly deficient in their 
responses to bacterial capsular polysaccharides, 
resulting in significant infant morbidity and mortality 
from infectious diseases. Antibody responses to 
complex polysaccharides (TI-2 antigens) are assumed 
to be T-cell independent. Experiments in mice that 
lack B1 cells have shown clearly that these cells are 
essential for anti-polysaccharide responses. Although 
neonates have relatively large numbers of CD5+ B 
cells, they are only responsive later in ontogeny. This 
could be due to the lack of the appropriate 
microenvironment. Responses to this class of antigen 
are predominantly of IgM and IgG3 isotype. The 
ability of these antigens to induce memory formation 
(which is T cell-dependent) is limited16. Recent 
improvements in our understanding of the cellular 
and molecular events that underpin memory 
generation provide the basis for a more detailed 
investigation of these observations. The need for this 
is strengthened by reports that show that TI-2 
antigens can influence B-cell development 
positively17 and induces phenotypic changes that 
could account for the priming effect.  
Some polysaccharide antigens can activate the 
complement cascade by the alternative pathway and; 
this appears to be important for their 
immunogenicity. The role of complement might be to 




augment B-cell responsiveness by allowing co-
ligation of the BCR and CD21 on B cells. Human 
neonatal cord-blood B cells are CD21+, although 
the molecule might be present at lower levels than 
on adult B cells18. CD21 appears to be functional 
on neonatal B cells, as they proliferate in response 
to Epstein-Barr virus (EBV). Importantly, 
neonatal human B cells that are unresponsive to 
type 4-pneumococcal polysaccharide can be 
induced to respond when their CD21 molecules 
are ligated with anti-CD21 mAb 19.  
Human neonates are, however, relatively 
deficient in C3, which only reaches adult levels at 
around one year of age 20, at about the same time 
as polysaccharide responses develop. Class 
switching is severely affected in C3-depleted 
mice; memory responses are ablated by 
complement depletion and C3-knockout mice 
exhibit severe defects in primary and secondary 
responses to TD antigens and in GC formation 21. 
Low C3 levels in neonates might therefore 
contribute to the low degree of isotype switching 
and defective generation of memory that are seen 
in their responses to TD antigens and to their 
deficient response to polysaccharides. These 
observations suggest that it would be interesting 
to examine the immunogenicity of both TD- and 
TI-antigen-C3 conjugates in neonates.  
 
Concluding remarks  
In conclusion, there are several mechanisms that 
might operate to produce the relative 
immunodeficiency that is seen in human neonates. 
Some might reflect developmentally regulated 
changes in B-cell signaling that could influence 
the establishment of effective interaction between 
T and B cells, which are necessary for secondary 
responses. Defective B-cell signaling might 
account for tilting of the immunity-tolerance 
balance in neonates and the reported bias of their 
T-cell responses towards those of Th2 type. 
Recent evidence also suggests that B cells are 
required to generate signals for the orderly 
development of lymphoid tissues, and that 
regulation of their ability to do so might be 
influential in determining the acquisition of 
responsiveness to polysaccharide antigens and the 
ability to generate memory responses.  
The estimated 1.8 million deaths annually 
from infection during the first year of life, 
predominantly in developing countries, is a 
daunting challenge. Immunology can play a major 
role in reducing this unacceptable level of 
mortality through effective neonatal and/or 
maternal vaccination. A full understanding of the 
neonatal immune system and its capacity to respond 
effectively to the diversity of antigens that will be 
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